Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 23, 2019

View Archived Issues

DNA damage repair protein Mus81 promotes migration of gastric cancer through regulation of ZEB1

TWEAK/Fn14 is upregulated in Crohn's disease and has a key pathogenic role in ileitis mouse models

Xeris initiates dosing in phase II study of fixed-ratio coformulation of pramlintide and insulin

A pancreatic (pro)enzyme mixture shows high efficacy against human pancreatic cancer stem cells

CAFs 'educated' by GoF p53-mutant pancreatic cancer cells promote metastasis and chemoresistance

Novel glomerulus-on-a-chip for renal disease modeling and drug testing

Boehringer and Inflammasome partner to develop novel therapies for retinal diseases

CStone announces clinical data for CS-1001, CS-1002 and CS-1003

FDA approves Pifeltro and Delstrigo for virologically suppressed adults with HIV-1 infection

Phase I data presented from the phase I/II STERIMGLI trial of durvalumab plus hFSRT

Rottapharm Biotech presents CR-13626, an oral tyrosine kinase inhibitor for the treatment of GBM

Karyopharm presents promising phase II safety and efficacy data for selinexor in rGBM

Lenti-D demonstrates the ability to stabilize neurologic disease progression in phase II/III study

Novartis discovers new endonucleases inhibitors

Reaction Biology Corp. describes HDAC/SIRT inhibitors

U.S. Department of Defense awards research grant to Novan

New PD-1 inhibitors disclosed by Bristol-Myers Squibb

Finding a balance in treating diabetic kidney damage

Beijing Scitech-Mq Pharmaceuticals patents wild-type EGFR, EGFR T790M mutant and HER2 inhibitors

DeNovaMed identifies bacterial acyl carrier protein synthase inhibitors

GenSight reports week 96 data from phase III RESCUE trial of GS-010 in LHON

FDA approves Rybelsus for type 2 diabetes

Immune responses, tumor reductions observed with Bria-IMT and pembrolizumab in phase I/IIa study

Phase IIa study assesses efficacy of vivax malaria vaccines ChAd63 PvDBP and MVA PvDBP

Syndax initiates phase I/II study of SNDX-5613 in relapsed or refractory leukemias

Crysvita approved in Japan for FGF-23-related hypophosphatemic rickets and osteomalacia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.